RxDoctor Payments Data

Adrian Marimon

Miami, FLNPI 1770718058

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Coopersurgical, Inc. at 28.5% of the total. Reporting peaked in 2022 at $687 and has fallen 64.4% since, to $245 in 2025.

$2,780in general payments, 2019–2025

Across 175 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopersurgical, Inc.$791
  • AbbVie$613
  • Hologic Sales And Service, LLC$165
  • Mission Pharmacal Company$134
  • Medical Device Business Services, Inc.$119
  • Evofem Biosciences, Inc.$86
  • plus $872 from 20 others
$296,371in research payments, 2019–2025

Across 82 payments — averaging $3614.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sumitomo Pharma America, Inc.$128K
  • AbbVie$127K
  • Myovant Sciences GmbH$40K
  • Bayer$2K

What the payments were for

  • Food & beverage$2,73999%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →